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&p.1:Abstract. The aim of the trial was to determine the diag-
nostic accuracy of scintimmammography with techne-
tium-99m methoxyisobutylisonitrile (99mTc-MIBI) in the
detection of primary breast cancer and to verify its clini-
cal usefulness. A total of 246 patients with a suspicious
breast mass or positive mammogram were included in
this prospective European multicentre trial. At 5 min and
60 min (optional) p.i. two lateral prone images were ac-
quired for 10 min each; 30 min p.i. one anterior image
was acquired for 10 min. There were 253 lesions (195
palpable and 58 non-palpable), in respect of which his-
tology revealed 165 cancers and 88 benign lesions. Insti-
tutional and blinded read results were correlated to core
laboratory histopathology results obtained during exci-
sional biopsy. Diagnostic accuracy for the detection of
breast cancer was calculated per lesion. The overall sen-
sitivity and specificity of blinded read scintimammogra-
phy were 71% and 69%, respectively. For palpable le-
sions, the sensitivity of blinded read and institutional
read scintimammography was 83% and 91%, respective-
ly. Sensitivity was not dependent on the density of the
breast tissue. Invasive ductal and invasive lobular can-
cers showed similar sensitivity. The sensitivity and spec-
ificity of mammography were 91% and 42%, respective-
ly, and did not depend on the tumour size. In 60% of
false-negative mammograms, 99mTc-MIBI was able to
diagnose malignancy (true-positive). High-quality imag-
ing with 99mTc-MIBI has a high diagnostic accuracy for
the detection of primary breast cancer. Used as a com-
plementary method, scintimammography with 99mTc-
MIBI can help to diagnose breast cancer at an earlier
stage in patients with dense breasts.
&kwd:Key words: Technetium-99m methoxyisobutylisonitrile –
Scintimammography – Breast cancer – Dense breasts –
Mammography
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Introduction
Breast cancer accounts for the highest proportion of can-
cer-related deaths among women [1, 2]. Over recent de-
cades, it has been shown that the incidence of this malig-
nant disease has increased and is still increasing [3]; this
is especially true in younger age groups. It seems possi-
ble that mortality might be reduced by therapeutic ap-
proaches as well as by efficient diagnostic methods. A
significant benefit for the survival of breast cancer pa-
tients who are older than 50 years has been demonstrat-
ed using mammography as a screening method [4–6].
However, for patients younger than 50 years, a signifi-
cant reduction of mortality could not be proven. Yet, it is
in this patient group that major difficulties and frequent
delays in the diagnosis of breast malignancies are often
experienced [7]. The main reason for the diagnostic
problems is dense or hyperproliferative glandular breast
tissue which is typical for the premenopausal woman.
Therefore, lumpy and mammographically dense breasts
are frequent in this age group, and the sensitivity of pal-
pation and mammography is significantly decreased [8].
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Table 2. Patient population of the trial &/tbl.c:&tbl.b:







Patients: 232 patients, after exclusion of 
14 patients
Lesions: 253 lesions (21 patients with 
2 examined lesions
195 palpable and 58 non-
palpable lesions
Mean age: 54.5 years
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Studies have shown that tumour size correlates with
the frequency of axillary and distant metastases [9, 10].
For a cancer size of 1.5 cm, the rate of axillary disease
has been calculated to be about 30%, whereas cancers
with a size of 3 cm showed an increased rate of 48% [9].
Furthermore, 8 years after primary therapy of breast can-
cer, distant metastases occur with a probability of about
20% in the case of cancers of between 1 and 2.5 cm but
with a probability of 40% when cancers are between 3.5
and 4 cm in size [11]. It has been shown that distant me-
tastases correlate with mortality [12]. Thus, it is clear
that the earlier tumours are detected, the better will be
the survival rate of patients.
Recently, encouraging results have been obtained by
means of nuclear breast imaging using different radio-
pharmaceuticals such as fluorine-18 fluordeoxyglucose,
technetium-99m methoxyisobutylisonitrile (99mTc-
MIBI), thallium-201 chloride, 99mTc tetrofosmin, 99mTc
methylene diphosphonate, radiolabeled antibodies and
iodine-123 oestradiol [13–40]. A number of studies have
demonstrated high diagnostic accuracy of 99mTc-MIBI
for the detection of breast cancer [22–32]. Therefore,




The study has been a prospective open-label multicentre trial to de-
termine the diagnostic accuracy of 99mTc-MIBI scintigraphy for the
identification of malignant breast lesions in two groups of patients
(Fig. 1): (1) patients with mammographically detected, non-palpa-
ble breast abnormalities; (2) patients with breast abnormalities de-
tected by palpation. Further objectives have been: (3) to compare
the diagnostic accuracy of sestamibi imaging with that of mam-
mography, (4) to establish whether the diagnostic performance of
the imaging technique can be improved by modifying the method
of interpretation and (5) to acertain whether use of the two tech-
niques, scintigraphy and mammography, in conjunction provides a
better predictive capability than either technique used alone.
Axillary tracer uptake had been documented on the case report
forms. Since only a few patients showed axillary uptake of 99mTc-
MIBI, these data are not presented in this paper. It was not the aim
of the trial to evaluate 99mTc-MIBI for the detection of lymph
node metastases.
Patients
Inclusion and exclusion criteria for entry into the trial are listed in
Table 1. Data were received for 246 patients (Table 2), from a to-
tal of nine sites (Italy 71 patients, France 64 patients, Spain 42 pa-
tients, Germany 37 patients, Belgium including two centres, 21
patients, Great Britain 7 patients, Switzerland 4 patients). The da-
ta of centres recruiting less than 20 patients were pooled. Since no
Subjects who have undergone mammography and are positive 
for (a) at least one palpable breast abnormality detected 
by physical examination
OR
(b) at least one breast abnormality detected by mammography
within the previous 3 weeks and are scheduled to undergo 
excisional biopsy are ENROLLED
⇓
Bolus injection of 99mTc-MIBI administered within 3 weeks 
of mammography and physical examination
⇓
5 min p.i. start of 10-min lateral image acquisitions, 
followed by anterior image
⇓
10-min lateral acquisition repeated 1 h p.i. (optional)
⇓
EXCISIONAL BIOPSY performed within 6 weeks 
following 99mTc-MIBI study
Fig. 1. Flow chart of the prospective trial with 99mTc-MIBI. &/fig.c:
Table 1. Inclusion and exclusion criteria for entry into the trial &/tbl.c:&tbl.b:
INCLUSION CRITERIA
1. Female older than 21 years, non-pregnant, non-lactating
2a. Suspicious lesion of the breast detected by physical
examination and scheduled for mammography within the 
next 3 weeks
2b. Suspicious lesion detected by mammography in the previous 
3 weeks
3. Recommendation for excisional biopsy, after mammography,
but within 6 weeks following 99mTc-MIBI study
4. Informed consent.
EXCLUSION CRITERIA
1. Previous mastectomy (modified) of breast with suspicious
lesion
2. Local tumour recurrence
3. Fine-needle biopsy within 1 week prior to scintimammography
4. Receipt of an investigational drug within 10 physical 
half-lives prior to 99m Tc- MIBI
&/tbl.b:
excisional biopsy had been performed, 14 patients were excluded
from the efficacy population, thus leaving 232 patients in this pop-
ulation. The overall ratio of palpable to mammographically de-
tected lesions was about 3:1. The number of lesions in the “by le-
sion” efficacy population was 253 (195 lesions detected by palpa-
tion and 58 lesions detected by mammography). In 21 cases, pa-
tients had two pathological lesions of the breast (ten bilateral can-
cers).
The mean age and weight for patients with palpable lesions
and mammographically detected lesions were 53.4 years and
63.1 kg and 56.4 years and 65.5 kg, respectively (range 21–87
years and 40–159 kg). The majority (95.5%) of patients were
Caucasian. A history of pregnancy was indicated for 74% of pa-
tients, with age at first pregnancy varying between 15 and 39
years (mean 24.5). In 18% of patients, a family history of breast
cancer was present. Oral contraceptive usage and hormone re-
placement therapy were indicated in 10% and 7%, respectively.
Sixty percent of women were postmenopausal. Pre- and peri-
menopausal status was documented in 30% and 8% of patients,
respectively. Surgical biopsy, found to be benign, had been previ-
ously conducted in 14% of patients. Mastectomy and lumpectomy
of the contralateral breast had been carried out in 4% and 6% of
patients.
Scintigraphy
Radiopharmaceutical. &p.2:The radiolabelling and quality control pro-
cedures for the preparation of 99mTc-MIBI (Dupont Pharma) were
carried out according to the manufacturer’s instruction. The vial
preparation requires reconstitution with sodium 99mTc pertechne-
tate followed by heating in a water bath. In order to be used, the
radiochemical purity of the radiopharmaceutical had to be greater
than or equal to 90%.
Patient preparation and administration. &p.2:Each patient received an
intravenous injection into the arm on the side contralateral to the
breast lesion. A “cold” injection with 10 ml saline solution was
administered after the injection of 99mTc-MIBI. The average dose
was 20 mCi (range 18–30 mCi). No meal was consumed between
injection and imaging; water intake was unrestricted, however.
When both breasts had a palpable or mammographically deter-
mined abnormality, the injection was given in a dorsalis pedis
vein.
The subject was initially examined in the prone position with
the arms raised above the head, the shoulders flat against the ta-
ble, and the head turned to one side. For lateral views, a special ta-
ble overlay was used to provide maximal separation of breast tis-
sue from the myocardium and the liver. This overlay consisted of
a foam cushion with two cut-offs at the lateral side. Then the pa-
tient was imaged in the supine position.
Imaging. &p.2:Planar imaging was started 5 min after the injection of
99mTc-MIBI. The imaging sequence was as follows: (1) 10-min
lateral view 90° acquisition of the breast with the suspected le-
sion, (2) 10-min lateral view 90° acquisition of the other breast,
following repositioning of the subject, (3) 10-min anterior view
with the subject positioned supine and her arms raised behind her
head. Delayed imaging 1 h post-injection was optional. Planar im-
ages were performed with a 256×256 matrix, a 10% window and
an energy peak of 140 keV. A low-energy high-resolution colli-
mated gamma camera without zoom was used. The camera was
positioned as close as possible to the breast. A minimum number
of 500 000 counts (field of view) per 40 cm head standardized had
to be acquired. For the first two subjects enrolled in the study at
each centre, 50 pixels in the breast were measured to allow com-
parative quantification.
Mammography
The analysis of mammograms is based on the institutional read. A
standard mammographic examination had to be applied to all pa-
tients. The mammographer assigned a probability of malignancy
(PM) for each lesion detected. If there was more than one lesion
in a breast, the PM was taken as the maximum recorded level for
that breast. When the probability was not given as a percentage,







If no lesion was detected mammographically in that breast, the
PM was assigned as zero. For analysis, PMs were grouped into or-
dered categories: 0%–24%, 25%–49%, 50%–74% and 75%–
100%. For the calculation of sensitivity/specificity statistics,
mammography was taken as indicating malignancy if the assessed
PM was 50% or greater.
Institutional and blinded read scintigraphy
For each lesion, a maximum of four images were assessed, an ini-
tial and a delayed image for both lateral and anterior views. The
delayed image was optional. Each set of images was assessed by
an institutional reader and a panel of four blinded readers. The in-
stitutional reader used both the initial and delayed images if avail-
able (but for the delayed image scored only the lateral view). The
blinded readers scored the initial and the delayed views separately
without knowing that they were from the same patient. For each
view, the image was assessed in each of a number of segments
[six per breast for the lateral view, four per breast for the anterior
view plus the axillary nodes (one score per breast)]. Each segment
was assessed using the following scale (Figs. 2 and 3):
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Fig. 2. Lateral scintimammography with 99mTc-MIBI in a 54-year-
old patient with a palpable lesion in the left breast. Focal accumu-
lation is observed in the upper part of the left breast, correspond-
ing to a histopathologically confirmed invasive ductal cancer (di-
ameter 2.0 cm). This scan was scored as 2 by the blinded read and
considered as a true-positive scintigram for definition 1 &/fig.c:
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0: Normal
1: Equivocal
2: Focal uptake – low intensity
3: Focal uptake – medium intensity
4: Focal uptake – high intensity
The blinded read was blinded in the sense that the assessors were
ignorant of the centre at which the images were taken, and of any
other ancillary medical information about the patient. Each asses-
sor scored the images independently.
For the primary assessment of diagnostic accuracy, any breast
with a maximum segment score of 2 or greater was interpreted as
a positive result (definition 1). A secondary assessment was also
made, in which a positive result was assumed if the maximum
score was 1 or greater (definition 2). For the blinded read, the as-
sessment based on the delayed view was made separately from
that using the early views, but only the information from the early
views was used for making comparisons with other assessment
methods.
For the interpretation of the blinded read panel results, a breast
was deemed to be positive if at least two of the four assessors
scored the breast as such. As only in 3% of the blinded read
scintigrams did two readers each score a scan positive and nega-
tive, there was no further consensus reading. Data had to be avail-
able for at least three of the assessors for this procedure to be ap-
plied; otherwise, the diagnosis was regarded as missing.
The blinded read assessors also scored the images for quality;
each of the four images (early and delayed, lateral and anterior)
was scored separately on a four-point scale: 1, excellent; 2, good;
3, fair; 4, poor. To obtain an overall assessment for each reader, an
average value for the four scores was calculated. To obtain an av-
erage across readers, the numerical average of 16 observations
(four readers by four views) was calculated.
Histopathology
An excisional biopsy was taken in all evaluated patients. This was
diagnosed by the institutional pathologist and the diagnosis was
later confirmed (in all but three cases) by the core centre patholo-
gist. The measurement of the tumour size was based on the insti-
tutional results. Analysis by tumour size was done for the largest
dimension given. Where two lesions were excised from the same
breast, the size of the larger lesion was used. The core centre diag-
nosis was taken as indicating malignancy (for the primary analy-
sis) if either of the following description boxes was ticked: (1)
type of invasive cancer, (2) ductal carcinoma in situ (DCIS). For a
secondary analysis, lobular carcinoma in situ (LCIS) and ductal
and/or lobular hyperplasia as indicators for an increased breast
cancer risk were also regarded as true-positive results.
Core centre histopathology diagnosed 109 invasive ductal and
29 invasive lobular cancers, 11 DCIS, two metastases, six tubular
carcinoma, two medullary carcinomas and two papillary carcino-
mas. Furthermore, one mucinous cancer, one case of Paget’s dis-
ease, one malignant cystosarcoma phylloides and one sarcoma
have been revealed. Among the benign alterations, there were 37
fibroadenomas, 25 fibrocystic changes, six fat necrosis, five in-
flammatory processes, four LCIS, three scleradenosis, three nor-
mal breasts, two scars, two adenomas and one hemangioma.
The tumour sizes reported at the main participating centres are
shown in Fig. 4. The average maximum tumour dimension ranged
from 1.3 cm (pooled centres) over 1.5 cm (France, Germany) and
2.0 cm (Italy) to 2.4 cm (Spain). Forty-one cancers had a maximal
diameter of below 1 cm, 37 a maximum diameter between 1.0 cm
and 1.5 cm and 87 a maximum diameter of more than 1.5 cm.
Data analysis
All data were collected on case report forms (CRFs) which had
been distributed to all participating centres. All CRF data were en-
tered into a database and converted to SAS datasets for delivery
and into STATA datasets for analysis.
The safety population of the trial consisted of all patients who
received the 99mTc-MIBI imaging agent. To be included in the ef-
ficacy population patients had to meet the following criteria: (1)
have had a biopsy for which a core centre microscopic diagnosis
exists, (2) have blinded read data for the scintigraphy. The so
called by lesion efficacy population consisted of all lesions for
which a core centre microscopic diagnosis exists. Some classes of
protocol violators were identified which were, however, not con-
sidered sufficient to warrant exclusion from the efficacy popula-
tion. These were: (1) no mammography (two patients), (2) mam-
mography more than 2 months prior to the scintigraphy (six pa-
tients who had no discrepancy between mammographic and scinti-
graphic results), (3) biopsy more than 6 weeks after the scintigra-
phy (19 patients, of whom four showed false-positive scintigrams
Fig. 3. Lateral scintimammography with 99mTc-MIBI in a 61-year-
old patient with a palpable lesion in the left breast. Slightly in-
creased tracer uptake is observed in the upper part of the left
breast. Histopathology revealed an invasive ductal cancer with a
maximum diameter of 1.1 cm. This scan was scored as 1 by the
blinded read and considered as a true-positive scintigram for defi-
nition 2 &/fig.c:
Fig. 4. Tumour size (mean maximum tumour dimension and range
of tumour size) according to the site of the participating centre
(pooled = all patients of the smaller centres) &/fig.c:
and one a false-negative scintigram). Among these 27 patients (12
malignant and 15 benign lesions), there were three false-negative
and five false-positive blinded read scintigrams referring to defini-
tion 2. The exclusion of these patients did not result in any altera-
tion in sensitivity and specificity as shown in the Results section.
All efficacy analyses were made separately for each target group
of patients: (1) mammographically detected breast abnormalities,
(2) breast abnormalities detected by palpation.
The measurement of agreement between any two assessment
methods was based on a two-by-two table, in which one of the
classifying factors was the gold standard (e.g. core centre histo-
pathological results). From the tables, the following statistics were
derived: sensitivity, specificity, overall agreement, kappa, positive
predictive value (PPV) and negative predictive value (NPV). For
the assessment of whether one technique is better than another,
four-by-four tables were created indicating false-negative and
false-positive, and true-negative and true-positive results of the
methods. Several different types of assessment were evaluated: (1)
institutional centre sestamibi read (definition 1 and definition 2)
compared to core centre histopathology, (2) blinded sestamibi
read (definition 1 and definition 2) compared to core centre histo-
pathology, 3. comparison between institutional and blinded read
scintigraphy, (4) comparison between blinded read scintigraphy
and mammography.
Safety assessment
The numbers of patients experiencing any adverse event were tab-
ulated. Adverse events had to be classified by type of event and




When the results of the blinded read were compared
with the histopathological results of the core centre,
scintigraphy was true-positive in 117 of 165 cancers
(definition 2). This resulted in an overall sensitivity of
71% (Table 3). In this group, sensitivity for palpable and
non-palpable cancers was 83% and 30%, respectively.
For tumours bigger than 1.5 cm, sensitivity was 90%.
For tumours between 1.0 and 1.5 cm and for those
smaller than 1 cm, sensitivity was 65% and 40%, respec-
tively.
If only scintigrams scored 2 or more were taken into
account (definition 1), overall sensitivity was only 61%.
In this group, sensitivity was 72% for the palpable
(n = 127) and 21% for the non-palpable cancers (n = 38;
Tables 3 and 4). For tumours bigger than 1.5 cm, sensi-
tivity was higher, with a value of 80%.
Among 88 benign alterations of the breast, there were
68 palpable and 20 non-palpable lesions (Table 5). Over-
all specificity was 69% (definition 2, 27/88 false-posi-
tives scans) and 81% (definition 1, 17/88 false-positive
scans). For palpable lesions, specificity was 75% (defint-
ion 2) and 79% (definition 1), respectively, and for le-
sions bigger than 1.5 cm, specificity was 72% (definition
2) and 78% (definition 1).
When the results of the blinded read were separated
out by main sites, the sensitivities and specificities were
as follows (definition 1, Table 6): 87% and 84% (Spain),
87% and 77% (Italy), 61% and 78% (Germany), 46%
and 100% (pooled centres) and 40% and 71% (France).
If the pooled smaller centres were excluded, the overall
sensitivity improved slightly to 63.5% but the specificity
remained constant at 80% (definition 1).
If the 27 patients with “acceptable” protocol viola-
tions were excluded, the overall sensitivity and specifici-
ty did not change, with values of 70.6% (108/153 true-
positives) and 70% (51/73 true-negatives), respectively
(definition 2).
Institutional read
If the histopathological results were correlated to the in-
stitutional read the overall sensitivity and specificity, the
PPV and the NPV were 88%, 66%, 84% and 72%, re-
spectively (for definition 2; Table 7). In this group, sen-
379
European Journal of Nuclear Medicine Vol. 25, No. 4, April 1998
Table 3. Sensitivities (Sens) and specificities (Spec) of blinded
read scintimammography according to the scoring mode &/tbl.c:&tbl.b:
All Palpable Non-palpable
(Sens/Spec) (Sens/Spec) (Sens/Spec)
Definition 1 61%/81% 72%/79% 21%/85%
Definition 2 71%/69% 83%/75% 30%/50%
Definition 1 = all lesions scored as 2 or more considered positive,
definition 2 = all lesions scored as 1 or more considered positive &/tbl.b:
Table 4. Results of blinded read scintimammography in respect of
malignant lesions (numbers in parentheses), according to the scor-
ing mode &/tbl.c:&tbl.b:
All (165) Palpable (127) Non-palpable (38)
Scoring mode TP FN TP FN TP FN
Definition 1 100 65 92 35 8 30
Definition 2 117 48 106 21 11 27
Definition 1 = all lesions scored as 2 or more considered positive;
definition 2 = all lesions scored as 1 or more considered positive;
TP, true-positives; FN, false-negatives &/tbl.b:
Table 5. Results of blinded read scintimammography in respect of
benign lesions (numbers within parentheses), according to the
scoring mode &/tbl.c:&tbl.b:
All (88) Palpable (68) Non-palpable (20)
Scoring mode TN FP TN FP TN FP
Definition 1 71 17 54 14 17 3
Definition 2 61 27 51 17 10 10
Definition 1 = all lesions scored as 2 or more considered positive;
definition 2 = all lesions scored as 1 or more considered positive;
TN, true-negatives, FP, false-positives &/tbl.b:
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sitivity for palpable and non-palpable lesions was 91%
and 60%, respectively. For tumours bigger than 1.5 cm,
sensitivity was 95%. For tumours between 1.0 and
1.5 cm and for those smaller than 1 cm, sensitivity was
74% and 55%, respectively.
If definition 1 was used the overall sensitivity and
specificity, the PPV and the NPV were calculated to be
81%, 74%, 86% and 65%, respectively. In this group,
sensitivity and specificity for palpable and non-palpable
lesions of the breast were 86% and 69%, and 63% and
81%, respectively.
The institutional results by main sites were as fol-
lows: sensitivity and specificifity were 93% and 83% for
the Italian centre, 87% and 80% for the Spanish centre,
83% and 56% for the German centre, 73% and 43% for
the French centre and 71% and 100% for the pooled cen-
tres (definition 1, Table 6). If the pooled smaller centres
were excluded, the overall sensitivity improved slightly
to 83% with a minimal decrease in specificity to 72%
(definition 1).
Mammography
When comparing mammographic results with the core
centre microscopy, mammography was true-positive in
152 of 165 cancers and true-negative in 37 of 88 benign
alterations of the breast. This results in a sensitivity and
specificity of 91% and 42%, respectively. Sensitivity
was not dependent on the size of the breast tumour (for
tumours >1.5 cm, 90.7%, for those between 1.0 and
1.5 cm, 96%, and for those <1.0 cm, 87%; non-palpable
88% and palpable 92%). In the category of probability
of malignancy of 50%–74%, mammography underesti-
mated the real cancer probability for palpable breasts but
overestimated it for non-palpable breasts. If mammogra-
phy and blinded read scintigraphy were compared, eight
cancers scored true-positive by the blinded read scintig-
raphy had been indicated by mammography to be false-
negative (Table 8). This means that in 61% of all false-
negative mammograms scintigraphy could diagnose the
cancer. The aforementioned eight cancers (seven palpa-
ble, one detected by ultrasonography) were studied by
different centres participating in the trial. Except for one
breast, the corresponding mammograms showed dense
breast tissue. In five of the eight malignant tumours, no
suspicious mass could be detected, and microcalcifica-
tions were present only in two breasts (Table 9). Just one
patient was postmenopausal.
Centre Italy France Spain Germany Pooled centre
Blinded read 87%/77% 40%/71% 87%/84% 61%/78% 46%/100%
(Sens/Spec)
Institutional 93%/83% 73%/43% 87%/80% 83%/56% 71%/100%
(Sens/Spec)
Sens, Sensitivity; Spec, Specificity &/tbl.b:
Table 6. Sensitivities and specificities of
blinded read and institutional scintimam-
mography separated by participating cen-
tres (referring to definition 1) &/tbl.c:&tbl.b:
Table 7. Sensitivities (Sens) and specificities (Spec) of institution-
al read scintimammography depending on the scoring mode &/tbl.c:&tbl.b:
All Palpable Non-palpable
(Sens/Spec) (Sens/Spec) (Sens/Spec)
Definition 1 81%/74% 86%/69% 63%/81%
Definition 2 88%/66% 91%/65% 60%/93%
Definition 1=all lesions scored as 2 or more considered positive;
definition 2=all lesions scored as 1 or more considered positive &/tbl.b:
Table 8 Comparison of mammographic and blinded read scinti-
graphic results (referring to definition 2) &/tbl.c:&tbl.b:
Mammographic Scintigraphic results
results
TP FP FN TN
TP 109 – 43 –
FP – 15 – 36
FN 8 – 5 –
TN – 12 – 25
TP, True-positives; FP, false-positives; FN, false-negatives; TN,
true-negatives &/tbl.b:
Table 9. Results of mammography, scintigraphy and histology in
patients showing a false-negative mammogram and a true-positive
scintigram &/tbl.c:&tbl.b:
Patient Breast MX PM SMM Histology
density
1 HeD MC, no mass 20% Acc,2 Inv. duct, G2
2 ExD MC, no mass 30% Acc, 3 Medullary, G3
3 HeD Mass 20% Acc, 3 Inv. duct, G2
4 HeD Mass 10% Acc, 2 Metastasis
5 ExD No mass 0% Acc, 2 Inv. lobular G1
6 ExD No mass 0% Acc, 2 Inv. duct, G2
7 NvD Mass 20% Acc, 2 Inv. duct, G1
8 HeD No mass 0% Acc, 3 Inv. duct, G1
MX, Mammography; SMM, scintigraphy; PM, probability of ma-
lignancy; HeD, heterogeneously dense; ExD, extremely dense;
NvD, numerous vague densities; MC, microcalcifications; Acc
2/3, focal accumulation with score 2 or 3; inv. duct, invasive duc-
tal carcinoma; inv. lobular, invasive lobular carcinoma &/tbl.b:
Density of breasts
Sensitivity of blinded read scintigraphy was not depen-
dent on the density of breast tissue. Of 165 cancers, 118
(72%) were categorized as located in a breast of mam-
mographic grade I or II density (group 1) and 47 (28%)
as located in a grade III/IV density breast (group 2). The
mean tumour diameter in groups 1 and 2 was 1.9 and
1.8 cm, respectively. Overall-sensitivity of the blinded
read scintigraphy (definition 2) for the first and second
groups was 70% (83 true-positives from 118 cancers)
and 72% (34 true-positives from 47 cancers), respective-
ly.
Time of imaging
As delayed images were optional, comparison of the ear-
ly and delayed blinded read scintigrams was confined to
176 breasts. Using definition 1, 30% of the breasts were
found to be positive on the early reads as compared with
26% on the delayed reads. Using definition 2, reads of
the early views yielded positive results in 38% compared
with 31% for the delayed reads. Only in three cases did
the early view give a false-negative result while the de-
layed read was true-positive.
Kappa-statistics
Overall, the agreement between the readers of the blind-
ed scintigraphy read did not show a significant differ-
ence if definition 1 was compared with definition 2.
Overall agreement referring to all breasts was high, at
0.812 and 0.793, respectively. In 97% of the cases, three
or more readers agreed in scoring a scintigram either
positive or negative (definition 1). The reader agreement
was somehow better for palpable lesions than for
mammographically detected lesions. This difference in
kappa values was more significant if definition 1 was
used. With decreasing quality of images, the kappa value
fell slightly but always remained above 0.7. In each
quality class, the same high percentage of reader agree-
ment (three or more readers scoring either positive or
negative) could be found with values of 94%–96%. One
main reason for disagreement between the readers was
the way axillary nodes have been handled. These were
entered as axillary nodes by some readers but as being in
one of the breast segments by others.
When comparing the blinded and the institutional
read, the overall kappa value for the agreement was 0.63.
For palpable lesions, the agreement was better, with a
value of 0.7. The decrease in kappa values with the qual-
ity score was more significant than mentioned before be-
tween the blinded readers. The main reason for the dif-
ferences in diagnoses of blinded and institutional reads
was that the institutional readers assigned higher scores
to lesions than did the blinded readers, especially where
the lesion was indistinct.
Histopathology
With regard to the histopathological characterization of
the cancer, the sensitivity of the blinded read (definition
2) for invasive ductal cancers (80 true-positives from
109), invasive lobular cancers (20 true-positives from
29) and ductal carcinoma in situ (seven true-positives
from 11) was 74%, 69% and 64%, respectively. The
blinded read correctly diagnosed two metastases, two
medullary cancers, one sarcoma and one malignant cys-
tosarcoma phylloides. Among six tubular and two papil-
lary cancers, blinded read scintigraphy was true-positive
in three and one cases, respectively, but could not diag-
nose one mucinous carcinoma and one case of Paget’s
disease (Table 10).
If the histopathological results of the benign altera-
tions are taken into account, specificity for fibroadeno-
mas and fibrocystic disease was 68% and 88% (definition
2), respectively. Among the six cases of fat necrosis, five
inflammations of the breast, two scars and one haemangi-
oma, blinded read scintigraphy was true-negative in four,
two, one and one cases, respectively. In two adenomas
and three cases of normal breast tissue, results were true-
negative in two cases each. All three breasts with sclerad-
enosis showed false-positive scintigrams (Table 11).
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Table 10. Results of scintimammography (SMM; definition 2;
blinded read) according to the histological type of breast cancer &/tbl.c:&tbl.b:
Histology No. TP-SMM FN-SMM
Inv. ductal 109 80 29
Inv. lobular 29 20 9
DCIS 11 7 4
Tubular 6 3 3
Others 10 7 3
All 165 117 48
Inv., Invasive; DCIS, ductal carcinoma in situ; TP-SMM, true-pos-
itive SMM; FN-SMM, false-negative SMM &/tbl.b:
Table 11. Results of scintimammography (SMM; definition 2;
blinded read) according to the histological type in benign lesions &/tbl.c:&tbl.b:
Histology No. TN-SMM FP-SMM
Fibroadenoma 37 25 12
Fibrocystic tissue 25 22 3
Fat necrosis 6 4 2
Inflammation 5 2 3
LCIS 4 4 0
Others 11 4 7
All 88 61 27
LCIS, Lobular carcinoma in situ; TN-SMM, true-negative SMM;
FP-SMM, false-positive SMM &/tbl.b:
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Discussion
Recently, nuclear breast imaging has gained significant
interest as several radionuclides have demonstrated
promising results in the diagnosis of breast cancer.
99mTc-MIBI is a cationic complex which can accumulate
in tumour cells [41]. The accumulation of 99mTc-MIBI in
the tumour is dependent on the quantity of mitochondria
in the tumour cell, on the electric membrane potential
and on the expression of the multidrug resistance (MDR)
gene [42–46].
Recent studies using 99mTc-MIBI for breast cancer
detection have shown high sensitivity and specificity for
palpable cancers [22–32]. For non-palpable breast le-
sions, diagnostic accuracy has been less favorable [25,
27, 29, 30]. In this trial, scintigraphy with 99mTc-MIBI
read blinded achieved an overall sensitivity of 71%. For
palpable tumours and tumours bigger than 1.5 cm, sensi-
tivity was 83% and 90%, respectively. Specificity in
these two groups was clearly over 70%. These values are
slightly below those reported by previous studies
[23–30]. Generally, it can be expected that it will be
more difficult to obtain similar results if the method is
assessed by a blinded multicentre study. Consequently,
in this trial, the institutional read demonstrates an in-
crease in the overall sensitivity in all centres up to a val-
ue of 88% when compared with the blinded read. It must
be supposed that the clinical data such as size of lesion,
location and probability of malignancy are important
factors for the reader of scintigraphy and their knowl-
edge will increase sensitivity. In the case of palpable le-
sions and lesions bigger than 1.5 cm, sensitivity in-
creased to 91% and 96%, respectively, by the institution-
al read. These results are in agreement with a multicen-
tre trial conducted in the United States and Canada
which revealed an institutional sensitivity of 95% for
palpable lesions [47].
In this study, it has been shown that sensitivity can be
significantly increased if lesions which are scored as
equivocal are considered as a malignant process. Even if
this definition was used, specificity did not fall below a
level of 70%. This means that any abnormality must be
considered as suspicious for malignancy. In this way, a
high sensitivity of scintimammography in association
with an acceptable specificity can be achieved (Fig. 5).
As demonstrated by the ROC curves, there will be a
learning process for the interpretation of scintigrams re-
sulting in an increase in sensitivity.
There are still significant limitations to the use of
mammography for the detection of breast cancer, and
these limitations persist in spite of technical improve-
ments facilitating dianosis. Especially in younger wom-
en (less than 50 years old) with dense breasts, the diag-
nostic benefit of mammography is less favourable [7, 8].
Thus, there is a need for a non-invasive method to com-
plement mammography and to help differentiate benign
and malignant breast lesions in dense breasts. Such a
method should be reliable and have a high sensitivity
and a high predictive value. In this trial, mammographic
results were within the range of the values reported in
the literature [48]. Overall sensitivity and specificity
were 91% and 40%, respectively. Sensitivity of mam-
mography was not dependent on the tumour size, and,
therefore, no decrease in sensitivity in patients with non-
palpable cancers was observed. In this trial, overall sen-
sitivity of mammography was superior to that of scintig-
raphy, demonstrating that scintimammography, in its
current state, is not suitable for breast cancer screening.
For the mammograms, only an institutional read has
been performed. This means that the mammographic re-
sults of this trial correspond to those of the clinical ev-
eryday practice of the radiologist.
However, this trial has shown that scintigraphy can
provide additional information to mammography and
help to detect breast cancer earlier in a subgroup of pa-
tients. In 60% of patients with a false-negative mammo-
gram, scintigraphy could diagnose the breast cancer.
This group consisted of younger patients with mammo-
graphically dense breast tissue resulting in a false-nega-
tive mammogram. As this study was able to prove, the
diagnostic accuracy of scintimammography is not de-
pendent on the density of breast tissue. This has also
been reported by Khalkhali et al. [49, 50]. Consequently,
premenopausal patients whose mortality from breast
cancer cannot be decreased significantly by screening
mammography will benefit most from scintimammogra-
phy.
In the majority of the cases, the woman herself de-
tects an alteration of the breast for which she consults
the physician [51]. Sensitivity of breast palpation is not
satisfactory, and often lumpy breasts make it difficult to
characterize sufficiently a palpable nodule or mass in the
breast [51]. If mammography performed in the further
diagnostic work-up is indeterminate and suspicion of
malignancy not high, the patient will be advised to re-
turn for a control mammography in 3–6 months. In this
Fig. 5. ROC curves of blinded and institutional (institut) read
scintigraphy for all and for palpable (palp) lesions. The first value
of each curve refers to definition 1 and the second value of the
curve refers to definition 2 &/fig.c:
patient group, the majority of which comprises premeno-
pausal women, scintigraphy could help to diagnose
breast cancer at an earlier point in time when it is used
as a complementary method to mammography (Fig. 6).
It is important for a breast cancer imaging modality
that sensitivity is not dependent on the histological type
of the cancer. For invasive ductal and lobular carcino-
mas, the sensitivity of scintimammography did not show
a significant difference. This group of malignant tu-
mours represent 80%–85% of all breast cancers [52]. For
DCIS, sensitivity was slightly lower than for invasive
cancers. Furthermore, less frequent cancers such as med-
ullary and tubular carcinomas and metastases could also
be diagnosed by scintimammography. This makes scin-
tigraphy suitable as a complementary imaging method.
False-positive results were obtained in patients with
fibroadenoma, fibrocystic disease and local inflamma-
tion of the breast. Disease with a high inflammatory
component might yield false-positive results, most likely
due to increased local perfusion. Areas with increased
mitochondrial activity and density, such as juvenile ade-
nomas and hyperproliferative disease, can also cause
false-positive MIBI uptake [22, 25, 27, 29]. However,
patients with atypical hyperproliferative disease have a
higher relative risk for breast cancer [52]. In these pa-
tients, a positive MIBI scan may be of prognostic value
[53].
The exact localization of a MIBI-positive area re-
mains a problem since neither planar imaging nor single-
photon emission tomography provides the surgeon with
sufficient information for biopsy of breast tissue. When
scintimammography is indicative for breast cancer but
other breast imaging modalities such as mammography,
ultrasonography and magnetic resonance imaging are
negative, the scintigram must be used for tumour local-
ization. New approaches have been developed to allow
scintigraphy-guided biopsy of breast lesions [54, 55].
It is known that mammogaphy is a very reader-depen-
dent method. With regard to ultrasonography, this prob-
lem is even more important. The interreader agreement
for scintimammography, however, is very high, with
kappa values of 0.812. It is important for a diagnostic
method that the interreader variation is low, especially
when it is performed in a wide medical field of clinical
everyday practice.
Khalkhali et al. have shown that the prone position
with the breasts hanging freely is the best technique for
the performance of lateral scintimammography because
deeper regions of the breast can be visualized [23]. For
this purpose different techniques may be used: a special
table design with a lateral cut-off or a kind of foam
cushion with lateral apertures as used in this trial. Re-
gardless of which technique is used, the breast must not
be compressed from either side. Furthermore, a high-res-
olution gamma camera should be used and the acquisi-
tion time must be at least 10 min if good quality images
are to be obtained. Special attention must be drawn to
the distance between the collimator and the breast,
which, ideally, should touch the camera surface. Stan-
dardization of scintimammography will help to achieve a
high quality level of this technique.
Use of fluorine-18 fluorodeoxyglucose (18F-FDG)
and positron emission tomography (PET) has also been
evaluated for the detection of breast cancer [14–21]. In a
larger patient group, Avril et al. reported a sensitivity
and specificity for the detection of primary breast cancer
of 88% and 78%, respectively [18]. For small tumours,
only low sensitivity was achieved. In a group of 20 pa-
tients, Palmedo et al. compared FDG PET and 99mTc-
MIBI scintimammography [19]; however, in 40 breasts
with 22 lesions, FDG PET could not detect additional
cancer in comparison with Tc-99m MIBI scintigraphy.
Comparing these two imaging modalities, PET has the
advantage of providing better spatial resolution, but the
availability of FDG and PET is limited and costs are sig-
nificantly higher.
Conclusions
Scintimammography with 99mTc-MIBI has a high diag-
nostic accuracy in palpable breast lesions. Sensitivity is
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Fig. 6. Flow chart indicating the role
of scintimammography in the diagnos-
tic work-up of patients with palpable
breast masses &/fig.c:
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not dependent on the mammographically determined
density of the breast tissue. Scintimammography is suit-
able as a complementary method to mammography in
patients with dense breasts and an intermediate or low
probability of breast cancer. Further, patients with a high
risk of breast cancer may benefit from radionuclide im-
aging with 99mTc-MIBI.
&p.2:Acknowledgements. The authors thank Ms. M. Grace for coordi-
nating the collaboration during the trial and for setting up the da-
tabase of the study.
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